Under this strategic arrangement, Cipla will distribute and promote Yurpeak, marking the second brand of tirzepatide to be launched in the country. Shares of Cipla Ltd ended at ₹1,645.00, down by ₹18.60, or 1.12%, on the BSE.
Under this strategic arrangement, Cipla will distribute and promote Yurpeak, marking the second brand of tirzepatide to be launched in the country. Shares of Cipla Ltd ended at ₹1,645.00, down by ₹18.60, or 1.12%, on the BSE.